Home > Publications database > Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. > print

001     178896
005     20240229143559.0
024 7 _ |a 10.1097/HS9.0000000000000688
|2 doi
024 7 _ |a pmid:35187406
|2 pmid
024 7 _ |a pmc:PMC8849404
|2 pmc
024 7 _ |a altmetric:123450445
|2 altmetric
037 _ _ |a DKFZ-2022-00327
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liebers, Nora
|b 0
245 _ _ |a Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis.
260 _ _ |a [Philadelphia, Pennsylvania]
|c 2022
|b Wolters Kluwer Health
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1650631466_2602
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Schönland, Stefan O
|b 1
700 1 _ |a Speer, Claudius
|b 2
700 1 _ |a Edelmann, Dominic
|0 P:(DE-He78)92820b4867c955a04f642707ecf35b40
|b 3
|u dkfz
700 1 _ |a Schnitzler, Paul
|b 4
700 1 _ |a Kräusslich, Hans-Georg
|b 5
700 1 _ |a Mueller-Tidow, Carsten
|b 6
700 1 _ |a Hegenbart, Ute
|b 7
700 1 _ |a Dietrich, Sascha
|b 8
773 _ _ |a 10.1097/HS9.0000000000000688
|g Vol. 6, no. 3, p. e688 -
|0 PERI:(DE-600)2922183-3
|n 3
|p e688
|t HemaSphere
|v 6
|y 2022
|x 2572-9241
909 C O |p VDB
|o oai:inrepo02.dkfz.de:178896
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)92820b4867c955a04f642707ecf35b40
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-08-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HEMASPHERE : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-13T18:57:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-13T18:57:08Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Double blind peer review
|d 2021-02-13T18:57:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b HEMASPHERE : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21